218 related articles for article (PubMed ID: 8994801)
1. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
Sekar N; Li J; Shechter Y
Crit Rev Biochem Mol Biol; 1996 Dec; 31(5-6):339-59. PubMed ID: 8994801
[TBL] [Abstract][Full Text] [Related]
2. [Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].
Beliaeva NF; Gorodetskiĭ VK; Tochilkin AI; Golubev MA; Semenova NV; Kovel'man IR
Vopr Med Khim; 2000; 46(4):344-60. PubMed ID: 11075417
[TBL] [Abstract][Full Text] [Related]
3. Insulino-mimetic and anti-diabetic effects of vanadium compounds.
Srivastava AK; Mehdi MZ
Diabet Med; 2005 Jan; 22(1):2-13. PubMed ID: 15606684
[TBL] [Abstract][Full Text] [Related]
4. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: mechanism of insulinomimesis.
Mehdi MZ; Srivastava AK
Arch Biochem Biophys; 2005 Aug; 440(2):158-64. PubMed ID: 16055077
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Holden RJ; Pakula IS; Mooney PA
Med Hypotheses; 1999 Apr; 52(4):319-23. PubMed ID: 10465670
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?
Cam MC; Brownsey RW; McNeill JH
Can J Physiol Pharmacol; 2000 Oct; 78(10):829-47. PubMed ID: 11077984
[TBL] [Abstract][Full Text] [Related]
7. Oral insulin-mimetic compounds that act independently of insulin.
García-Vicente S; Yraola F; Marti L; González-Muñoz E; García-Barrado MJ; Cantó C; Abella A; Bour S; Artuch R; Sierra C; Brandi N; Carpéné C; Moratinos J; Camps M; Palacín M; Testar X; Gumà A; Albericio F; Royo M; Mian A; Zorzano A
Diabetes; 2007 Feb; 56(2):486-93. PubMed ID: 17259395
[TBL] [Abstract][Full Text] [Related]
8. Arylalkylamine vanadium salts as new anti-diabetic compounds.
Zorzano A; Palacín M; Marti L; García-Vicente S
J Inorg Biochem; 2009 Apr; 103(4):559-66. PubMed ID: 19246098
[TBL] [Abstract][Full Text] [Related]
9. Insulin signal mimicry as a mechanism for the insulin-like effects of vanadium.
Mehdi MZ; Pandey SK; Théberge JF; Srivastava AK
Cell Biochem Biophys; 2006; 44(1):73-81. PubMed ID: 16456236
[TBL] [Abstract][Full Text] [Related]
10. Vanadium compounds as insulin mimics.
Orvig C; Thompson KH; Battell M; McNeill JH
Met Ions Biol Syst; 1995; 31():575-94. PubMed ID: 8564818
[TBL] [Abstract][Full Text] [Related]
11. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
12. Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes.
Seale AP; de Jesus LA; Kim SY; Choi YH; Lim HB; Hwang CS; Kim YS
Biotechnol Lett; 2005 Feb; 27(4):221-5. PubMed ID: 15742140
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Harley EA; Levens N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine phosphatase 1B inhibitors for diabetes.
Johnson TO; Ermolieff J; Jirousek MR
Nat Rev Drug Discov; 2002 Sep; 1(9):696-709. PubMed ID: 12209150
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like properties of vanadium: a curiosity or a perspective for the treatment of diabetes?
Brichard SM; Lederer J; Henquin JC
Diabete Metab; 1991; 17(5):435-40. PubMed ID: 1752343
[TBL] [Abstract][Full Text] [Related]
16. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
17. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
18. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase.
Holland W; Morrison T; Chang Y; Wiernsperger N; Stith BJ
Biochem Pharmacol; 2004 Jun; 67(11):2081-91. PubMed ID: 15135305
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats.
Dadke SS; Li HC; Kusari AB; Begum N; Kusari J
Biochem Biophys Res Commun; 2000 Aug; 274(3):583-9. PubMed ID: 10924321
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Tobin JF; Tam S
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):500-12. PubMed ID: 12197308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
